An interventional study of Smartphone-enabled structured exercise therapy (SE-SET) and Standard exercise therapy in Peripheral Arterial Disease, sponsored by Emory University. Completed at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2025-03-13.
Sponsored by Emory University · Not applicable, Interventional, and Treatment
Among 479 studies in Peripheral Arterial Disease with a site in United States — 82 open to participants now, 101 under way, 10 of them phase 3. Peripheral Arterial Disease · United States.
Among the 479 studies in Peripheral Arterial Disease with a site in United States, this one is the 211th largest by enrollment of the 373 interventional ones that give a count, is one of 24 that started in 2018, is one of 217 with no phase, and was the 275th registered.
1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.
Browse Peripheral Arterial Disease studies →82 of the 479 studies in Peripheral Arterial Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States, United Kingdom
Shanghai CureGene Pharmaceutical Co., Ltd. · Sites in United States
University of Tennessee Graduate School of Medicine · Sites in United States
Cook Research Incorporated · Sites in United States
University of Nebraska · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 192 Peripheral Arterial Disease studies recruiting now, 138 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 89 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
479 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 49 · Phase 2 65 · Phase 3 35 · Phase 4 25
First in 1992; this study’s year is marked. 24 started in 2018.
This study's enrollment of 46 is below the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 64 across the 373 interventional studies, 125 across the 103 observational. Of the 335 that completed or were terminated, 155 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
189 of 479 have an industry lead sponsor. The 10 most frequent:
Emory University is the lead sponsor of 1,405 studies on the registry; 225 are open to participants now.
Of its 237 completed or terminated interventional studies of FDA-regulated products, 178 (75%) have results posted.
Emory University has 3 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
36 of the studies in Peripheral Arterial Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04794530Phase 3Northwestern UniversityThe COCOA-PAD II Trial | 2026-12-31 |
| NCT05132439Phase 3VA Office of Research and DevelopmentMetfOrmin BenefIts Lower Extremities With Intermittent Claudication | 2027-02-28 |
| NCT07639853Medtronic EndovascularCase-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils | 2026-11 |
| NCT06321575Nipro Vascular Innovations Americas, IncThe Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial) | 2026-11 |
| NCT06399809Northwestern UniversityFisetin to Reduce Senescence and Mobility Impairment in PAD | 2026-11 |
Among the 479 studies in Peripheral Arterial Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aim is to evaluate the effectiveness of a coached, smartphone-enabled exercise program versus physician directed exercise therapy (usual care).
Structured exercise therapy is a first line treatment for symptomatic peripheral artery disease, but compliance is poor. Coaching programs may help but requires significant resources. Smartphone programs may increase the efficiency of such efforts. The study aim is to evaluate the effectiveness of a coached, smartphone-enabled exercise program versus physician directed exercise therapy (usual care) in patients at Grady Memorial Hospital's vascular clinic.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
And one of the following:
Exclusion Criteria:
Life-threatening process including:
Condition other than PAD that limits walking before claudication onset
This includes, but is not limited to:
Active behavioral conditions such as uncontrolled schizophrenia or illicit drug addiction that, in the opinion of the study team, will interfere with active participation
Inability to attend study visits
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm involves a smartphone app Movn - rehabilitation platform based on MULTIFIT, a case-management system for secondary prevention and patient surveillance after acute MI. The key features of the smartphone app include daily reminders to exercise, virtual diary for patients to enter data on exercise sessions, two-way secure messaging with the health coach, and educational videos on heart and vascular health.
Behavioral: Smartphone-enabled structured exercise therapy (SE-SET)
Self-directed, unsupervised exercise as prescribed by the patient's physician.
Behavioral: Standard exercise therapy
The SE-SET program lasts a total of 12 weeks per participant. During this time, the application will automatically track physical activity (steps) and subjects will be prompted to enter other health data such as blood pressure and weight and watch brief educational videos on topics such as smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education. Patients will be contacted by a member of the study team weekly via phone call to identify barriers to patient compliance (issues related to exercise tracking, medication issues that prevent patients from being active, high BP/weight issues) and help patients navigate those barriers. Movn participants can also send direct messages to the study team to ask about non-urgent matters related to their care.
The Standard exercise therapy lasts a total of 12 weeks per participant. Participants will be counseled by the physician to perform exercise at home, including 3 times per week of walking 30+ minutes; if applicable, the physician will also counsel on smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education. These patients will be given a fitness band, which will be set up by the study team using a de-identified study account that will provide additional data on their progress over time.
Change in 6-minute walk test (6MWT) distance completed
The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
Time frame: Immediately before and after the 12-week period
Change in Walking Impairment Questionnaire (WIQ) score
WIQ measures self-reported walking distance, speed, and stair-climbing ability. In the WIQ distance score, the participant is asked to assess the degree of walking difficulty in walking specific distances on a scale from 0 to 4. A score of 0 represents the inability to walk the distance and a score of 4 represents no difficulty. WIQ speed score assesses the degree of difficulty in walking one block at specific speeds, ranging from walking slowly to jogging, on a scale of 0 to 4. In the WIQ stair-climbing score, the participant is asked to report the degree of difficulty climbing specific numbers of flights of stairs, ranging from one to three flights of stairs, on a scale of 0 to 4. This graded score is multiplied by a prespecified weight for each distance, speed, or number of stair flights. The products are summed and divided by the maximum possible score to obtain a percent score, ranging from 0 (inability to perform any of the tasks) to 100 (representing no difficulty).
Time frame: Immediately before and after the 12-week period
Change in Physical Health Composite Score of SF-36
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. To calculate the scores it is necessary to use special software. The eight sections are: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health.
Time frame: Immediately before and after the 12-week period
Change in claudication onset time during 6MWT
One typical symptom of peripheral arterial occlusive disease' (PAOD) is claudication , which is defined as pain, cramps, numbness or a sense of fatigue in the muscles associated with walking, in one or both lower limbs, affecting either the distal or proximal muscle groups.
Time frame: Immediately before and after the 12-week period
Change in ankle-brachial pressure index (ABPI)
The ankle-brachial pressure index (ABPI) is the ratio of the blood pressure at the ankle to the blood pressure in the upper arm (brachium). Compared to the arm, lower blood pressure in the leg suggests blocked arteries due to peripheral artery disease (PAD). The ABPI is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressure in the arm.
Time frame: Immediately before and after the 12-week period
Change in number of steps/week
Number of steps/week will be obtained from participants' fitness trackers
Time frame: Immediately before and after the 12-week period
Critical Limb Ischemia
Number of Critical Limb Ischemia events reported by participants
Time frame: Over the 12-week study period
Other Cardiovascular Outcomes
Number of Cardiovascular Outcomes other than Critical Limb Ischemia events reported by participants
Time frame: Over the 12-week study period
Exercise-Related Injury
Number of Exercise-Related Injury events reported by participants
Time frame: Over the 12-week study period
Mortality
Number of deaths
Time frame: Over the 12-week study period
Ran from Aug 2018 to primary completion in Feb 2025, 77 months.
Of 260 non-industry interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's 77 months is above that.
Counting every sponsor, half of 385 studies reached it within 31 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.